Biomarker: F422-IgE Ara h 1

Overview

Ara h 1 is a major allergenic protein in peanut (Arachis hypogaea), also called groundnut. It is a heat-stable 7S globulin, or vicilin-type seed storage protein, found primarily in the edible peanut seed. Sensitization to Ara h 1 may contribute to IgE-mediated reactions after eating peanut, including immediate symptoms such as urticaria, gastrointestinal symptoms, respiratory symptoms, or anaphylaxis. Exposure most commonly occurs through ingestion of peanut or peanut-containing foods, and evaluation of serum Ara h 1-specific IgE may help characterize peanut sensitization when interpreted with clinical history and other testing. A positive result indicates sensitization and does not, by itself, establish clinical peanut allergy.

Clinical Use Cases

Evaluation of suspected IgE-mediated peanut allergy: Serum Ara h 1-specific IgE may support the evaluation of a patient with a history suggestive of an immediate reaction to peanut.
Assessment of peanut component sensitization: Testing can identify IgE directed against Ara h 1 rather than only against whole-peanut extract.
Interpretation of an uncertain peanut allergy history: Ara h 1 may be assessed with whole-peanut serum-specific IgE, other peanut components, and the clinical history when the relationship between peanut exposure and symptoms is unclear.
Differentiation of sensitization patterns: Component testing may help distinguish sensitization to peanut storage proteins, including Ara h 1, from patterns involving cross-reactive components such as Ara h 8 or Ara h 9.
Support for decisions about further evaluation: Results may help an allergist determine whether additional assessment, including a medically supervised oral food challenge, is appropriate. Component testing cannot reliably determine the eliciting dose or reaction severity and should not replace clinical evaluation or food challenge when indicated.
Research on peanut allergy biomarkers: Ara h 1-specific IgE has been studied as a biomarker associated with objectively confirmed peanut allergy, although Ara h 2 generally demonstrates stronger diagnostic performance.

Specimen Types

Serum: The standard specimen for measuring Ara h 1-specific IgE in blood-based component testing.
Plasma: May be accepted by some validated laboratory methods, although serum is the commonly described specimen for clinical allergen-specific IgE measurement.

Measurement Methods

Allergen-specific IgE testing: Measures IgE antibodies in serum directed against Ara h 1. Results are generally reported as an allergen-specific IgE concentration or class using the assay’s validated reporting system.
Component-resolved diagnostics: Measures IgE to individual peanut proteins, including recombinant or purified Ara h 1, rather than measuring IgE only to whole-peanut extract. This approach may help characterize molecular sensitization patterns.
Whole-peanut serum-specific IgE: Usually performed as part of the broader evaluation and interpreted alongside Ara h 1, other peanut components, and the clinical history.
Clinical correlation and oral food challenge: A supervised oral food challenge may be used when the diagnosis remains uncertain. It is not a laboratory method, but it remains the reference approach for confirming or excluding clinical food allergy in appropriate patients.

Test Preparation and Influencing Factors

Fasting: Fasting is generally not required for serum-specific IgE testing unless other blood tests collected at the same time require it.
Medications: Most medications do not prevent measurement of serum-specific IgE. Medication review remains important because drugs such as beta-blockers or other agents may affect the safety or management of an oral food challenge, rather than the laboratory measurement itself.
Clinical history: Timing of symptoms, amount and form of peanut consumed, reproducibility, and objective findings determine the pretest probability and are essential for interpretation.
Sensitization versus allergy: Detectable Ara h 1-specific IgE demonstrates immunologic sensitization, not necessarily symptomatic peanut allergy. A positive result should not be interpreted independently of the patient’s history and, when necessary, supervised challenge testing.
Component profile: Ara h 1 results should be interpreted with other peanut components, particularly Ara h 2 and Ara h 3, because the overall component pattern may provide more information than an isolated Ara h 1 result.
Total IgE concentration: Very high or very low total IgE concentrations may influence the clinical interpretation of specific IgE results and the likelihood that a low-level result is meaningful.
Age and population: Diagnostic performance varies with age, geographic population, clinical selection, assay method, and the reference standard used. Ara h 1 has generally shown lower sensitivity than Ara h 2 in studies using oral food challenge as the reference standard.
Reaction severity: The concentration of Ara h 1-specific IgE should not be used alone to predict how severe a future reaction will be. Studies have not consistently shown that component sensitization predicts reaction severity or eliciting dose.
Assay characteristics: Results from different platforms, component preparations, and reporting units may not be directly interchangeable. Contamination of some purified natural preparations with other peanut proteins may also affect apparent IgE binding, making well-characterized recombinant components preferable for molecular testing in some contexts.

Cross-Reactivity

Vicilin proteins: Ara h 1 belongs to the vicilin family of seed storage proteins. Structurally related vicilins occur in other legumes and some tree nuts, creating a potential basis for IgE cross-reactivity.
Pea and lentil: Human immunologic studies and clinical reports describe cross-reactive IgE involving Ara h 1 and vicilin-related proteins in pea and lentil. This does not mean that every person sensitized to Ara h 1 will react clinically to those foods.
Soy and other legumes: Vicilin-related proteins in soybean and other legumes may show IgE cross-reactivity with peanut proteins. A positive test to peanut or another legume therefore requires clinical correlation rather than automatic avoidance of all legumes.
Tree nuts: Vicilin proteins in some tree nuts, including walnut, share IgE-binding regions with Ara h 1. Cross-reactive IgE binding can occur, but laboratory cross-reactivity is not equivalent to clinically confirmed peanut and tree-nut allergy.
Other peanut components: Ara h 1, Ara h 2, and Ara h 3 do not appear to have substantial immunologic cross-reactivity with one another; apparent cross-inhibition in some assays may result from contamination or assay-related effects rather than true clinically important cross-reactivity.
Clinical relevance: Cross-reactive sensitization may influence interpretation of serum component results, but symptoms after exposure to the related food must be assessed separately. Ara h 1 sensitization alone does not establish clinical allergy to peanut, pea, lentil, soy, or tree nuts.